...
首页> 外文期刊>Cell chemical biology >A Bacterial Expression Platform for Production of Therapeutic Proteins Containing Human-like O-Linked Glycans
【24h】

A Bacterial Expression Platform for Production of Therapeutic Proteins Containing Human-like O-Linked Glycans

机译:一种用于生产含有人样O-连接聚糖的治疗蛋白的细菌表达平台

获取原文
获取原文并翻译 | 示例

摘要

We have developed anEscherichia colistrain for thein?vivoproduction of O-glycosylated proteins. This was achieved using a dual plasmid approach: one encoding a therapeutic protein target, and a second encoding the enzymatic machinery required for O-glycosylation. The latter plasmid encodes human polypeptide N-acetylgalactosaminyl transferase as well as a β1,3-galactosyl transferase and UDP-Glc(NAc)-4-epimerase, both fromCampylobacter jejuni, and a disulfide bond isomerase of bacterial or human origin. The effectiveness of this two-plasmid synthetic operon system has been tested on three proteins with therapeutic potential: the native and an engineered version of the naturally O-glycosylated human interferon α-2b, as well as human growth hormone with one engineered site of glycosylation. Having established proof of principle for the addition of the core-1 glycan onto proteins, we are now developing this system as a platform for producing and modifying human protein therapeutics with more complex O-glycan structures inE.coli.
机译:我们已经开发了Anescherichia Colistrain的Thein?VivoCroduction对O-糖基化蛋白质。这是使用双质粒方法实现的:编码治疗蛋白靶标的一种,以及O-糖基化所需的第二编码酶机。后一种质粒编码人多肽N-乙酰甘烷氨基氨基转移酶以及β1,3-半乳糖基转移酶和UDP-GLC(NAC)-4-映异构酶,缺两种肌电杆菌jejuni和细菌或人源二硫键异构酶。这种二粒质粒合成型术术系统的有效性已在具有治疗潜力的三种蛋白质上进行测试:天然和工程形式的天然o-糖基化人干扰素α-2b,以及具有一个工程化糖基化部位的人生长激素。在将核心-1甘油中添加到蛋白质上的原则上建立了证据,我们现在正在开发该系统作为用更复杂的O-Glycan结构的生产和改性人类蛋白质治疗的平台.COLI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号